RGEN vs ALNY Stock Comparison: AI Score, Valuation, Performance and Upside
Repligen and Alnylam Pharmaceuticals both serve the broader biotechnology industry but from very different angles: Repligen supplies bioprocessing tools and consumables used to manufacture biologic drugs, while Alnylam develops its own RNA interference therapeutics targeting specific rare genetic and other diseases.
Repligen offers indirect, picks-and-shovels exposure to broad biopharmaceutical industry growth without single-drug risk, while Alnylam offers a more direct, platform-based bet on RNA interference therapeutics gaining commercial and pipeline traction. Consider whether you prefer Repligen's diversified tools exposure or Alnylam's concentrated therapeutic platform bet.
ALNY holds the edge across 3 of 5 key metrics in this comparison. RGEN has delivered stronger 1-year price return (+16.03% vs -65.35%), though ALNY has the better forward P/E setup (19.94x vs 65.57x for RGEN). ALNY leads on both revenue growth (66.90%) and operating margin (17.93%), suggesting a stronger fundamental setup on both dimensions. Analyst consensus implies meaningfully more upside for ALNY (+49.33%) than for RGEN (+8.53%).
Human Wall Street analysts' price targets, typically implying a ~12-month view — a separate signal from this site's own AI Prediction Signal further down the page, which is a 5-/30-day machine-learning forecast based on price history alone.
- Want indirect, picks-and-shovels exposure to broad biopharmaceutical industry growth
- Value a diversified customer base reducing dependence on any single drug's success
- Believe bioprocessing order recovery following post-pandemic destocking offers upside
- Prefer a recurring consumables revenue model over concentrated therapeutic development risk
- Want direct exposure to a pioneering RNA interference drug technology platform
- Believe an expanding portfolio of approved therapies validates the platform's commercial potential
- Are comfortable with pipeline execution risk tied to a relatively newer drug technology
- See value in a growing pipeline leveraging the same core technology across multiple disease areas
| Metric | RGEN | ALNY |
|---|---|---|
| AI scorei | 54.3 | 52.6 |
| AI ranki | #434 | #306 |
| Latest closei | $172.95 | $158.00 |
| 1M returni | -4.82% | -28.09% |
| 3M returni | +17.61% | -28.29% |
| 6M returni | +46.31% | -46.97% |
| 1Y returni | +16.03% | -65.35% |
How much would $10,000 be worth today if invested at the start of each period, with all dividends reinvested?
| Period | RGEN | ALNY |
|---|---|---|
| 1Y ago | $11.52K (+15.2%) started 2025-11-03 | $3.64K (-63.6%) started 2025-11-03 |
| 5Y ago | $5.92K (-40.8%) started 2021-11-03 | $9.14K (-8.6%) started 2021-11-03 |
| 10Y ago | $64.92K (+549.2%) started 2016-11-03 | $50.3K (+403.0%) started 2016-11-03 |
Hypothetical — past performance does not guarantee future results.
| Metric | RGEN | ALNY |
|---|---|---|
| Market capi | $9.76B | $33.28B |
| Trailing P/Ei | 236.90 | 43.32 |
| Forward P/Ei | 65.57 | 19.94 |
| Price/Salesi | N/A | N/A |
| EV/Revenuei | 12.28 | 6.86 |
| Analyst targeti | $187.70 | $371.35 |
| Target upsidei | +8.53% | +49.33% |
| Metric | RGEN | ALNY |
|---|---|---|
| Revenue growthi | 11.90% | 66.90% |
| Earnings growthi | -65.90% | N/A |
| EPS growthi | -65.90% | N/A |
| FCF margini | +14.45% | +5.65% |
| Operating margini | 9.31% | 17.93% |
| Profit margini | 5.29% | 16.13% |
| ROIC proxyi | 1.99% | 96.56% |
| Return on equityi | 1.99% | 96.56% |
| Dividend yieldi | N/A | N/A |
| Payout ratioi | 0.00% | 0.00% |
| Dividend growth streaki | N/A | N/A |
| Betai | 1.01 | 0.30 |
| Debt/equityi | 32.72 | 220.62 |
| Current ratioi | 9.05 | 3.06 |
| Quick ratioi | 7.30 | 2.79 |
Over the past year, RGEN and ALNY have moved weakly in the same direction (correlation of 0.18), based on daily returns.
Lower drawdown and smaller single-period drops generally indicate a smoother ride, though they do not guarantee lower future risk.
| Period | Metric | RGEN | ALNY |
|---|---|---|---|
| 1Y | Growthi | +15.17% | -63.60% |
| CAGRi | +15.22% | -63.72% | |
| Volatilityi | 46.60% | 54.52% | |
| Sharpe ratioi | 0.44 | -1.65 | |
| Sortino ratioi | 0.64 | -1.87 | |
| Max drawdowni | 40.28% | 66.62% | |
| Current drawdowni | 11.11% | 66.62% | |
| Avg drawdowni | 15.30% | 33.55% | |
| Ulcer Indexi | 19.36% | 36.77% | |
| Max daily dropi | 8.32% | 28.31% | |
| Max wkly dropi | 18.23% | 29.47% | |
| 5Y | Growthi | -40.84% | -8.60% |
| CAGRi | -9.97% | -1.78% | |
| Volatilityi | 51.40% | 51.82% | |
| Sharpe ratioi | -0.04 | 0.13 | |
| Sortino ratioi | -0.05 | 0.20 | |
| Max drawdowni | 64.81% | 67.84% | |
| Current drawdowni | 40.84% | 67.84% | |
| Avg drawdowni | 44.36% | 20.72% | |
| Ulcer Indexi | 45.76% | 25.27% | |
| Max daily dropi | 13.22% | 28.31% | |
| Max wkly dropi | 21.92% | 29.47% | |
| 10Y | Growthi | +549.21% | +403.02% |
| CAGRi | +20.58% | +17.54% | |
| Volatilityi | 46.36% | 52.51% | |
| Sharpe ratioi | 0.54 | 0.47 | |
| Sortino ratioi | 0.79 | 0.76 | |
| Max drawdowni | 68.27% | 67.84% | |
| Current drawdowni | 46.65% | 67.84% | |
| Avg drawdowni | 29.50% | 21.57% | |
| Ulcer Indexi | 36.94% | 26.53% | |
| Max daily dropi | 14.44% | 28.31% | |
| Max wkly dropi | 21.97% | 29.47% |
| Category | RGEN | ALNY |
|---|---|---|
| Company | Repligen Corporation | Alnylam Pharmaceuticals, Inc. |
| Sector | Healthcare | Healthcare |
| Industry | Medical Instruments & Supplies | Biotechnology |
| Core business | A life sciences company that develops and manufactures bioprocessing technologies and consumables used by biopharmaceutical companies to produce biologic drugs, positioning it as a picks-and-shovels supplier to the broader biotech industry. | A biotechnology company pioneering RNA interference therapeutics, a drug technology that silences disease-causing genes, with an expanding portfolio of approved and pipeline therapies addressing rare genetic and other diseases. |
| Investor focus | Bioprocessing equipment and consumables order recovery following a post-pandemic industry destocking cycle, new product adoption trends, and overall biopharmaceutical manufacturing capacity investment levels. | Commercial growth of approved RNA interference therapies, pipeline progress across new disease areas, and overall validation of RNA interference as a durable drug development platform. |
- Picks-and-shovels bioprocessing technology position provides indirect exposure to broad biopharmaceutical industry growth without single-drug risk
- Diversified customer base across many biopharmaceutical manufacturers reduces dependence on any single drug's commercial success
- Recurring consumables revenue model provides more stable, repeatable demand than one-time equipment sales alone
- Pioneering position in RNA interference therapeutics provides a differentiated, platform-based approach to drug development
- Expanding portfolio of approved therapies demonstrates successful translation of the RNA interference platform into commercial products
- Growing pipeline across multiple disease areas leverages the same core technology platform for diversified growth
- Bioprocessing demand has been affected by post-pandemic destocking cycles as customers worked down excess inventory
- Revenue growth is tied to broader biopharmaceutical manufacturing capacity investment, which can slow during industry funding downturns
- Faces competition from other life sciences tools and bioprocessing equipment suppliers
- RNA interference remains a relatively newer drug technology platform with less long-term commercial track record than traditional biologics
- Pipeline execution risk is elevated given the number of programs relying on continued platform technology validation
- Faces competition from other gene-silencing and RNA-based therapeutic approaches being developed by rival companies
Compare more than two at a time
This page is a fixed writeup on RGEN and ALNY. Our comparison engine is the interactive version: load up to five tickers, switch timeframes, and get the correlation, drawdown, and overlap analysis that a static page can't show.
Add three more names beside RGEN and ALNY, mixing stocks and ETFs in the same table — useful when the real question is which of a whole peer group to own.
AI score, forward P/E, analyst target upside, operating margin, and revenue growth are scored head-to-head, with a running tally of which ticker leads on how many metrics.
Volatility, Sharpe and Sortino ratios, maximum, current, and average drawdown, Ulcer Index, and worst single-day and single-week drops across every timeframe.
Pairwise daily-return correlation for every combination, so you can see whether two holdings actually diversify each other or just move together.
A scatter plot of forward P/E against return on equity, plus drawdown and 30-day rolling volatility charts, to separate what is cheap from what is merely beaten down.
For ETFs, a top-holdings comparison that exposes hidden overlap between funds. Every comparison exports to CSV for your own spreadsheet work.
Two comparisons a week are free without an account. A 14-day trial removes the limit and adds AI price forecasts, stock rankings, saved watchlists, and the intrinsic value calculator — no credit card required.
Want deeper AI forecasts?
This comparison page is public and free forever. Subscribers can unlock saved watchlists, full AI rankings, detailed forecasts, and interactive analysis tools.
Full valuation workup with AI Score, Monte Carlo forecast, and bull/bear case — free preview, premium data from $3.99.